Please assess the completion status of the following clinical trial:

Trial Title: Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Written Informed Consent~* Age≥ 17 and \<80 years,~* Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment)~* Oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment)~* HbA1c ≥ 7.0% and ≤10.0%~Exclusion Criteria:~* Women of child bearing potential~* body mass index (BMI)≥35 Kg/m2 or BMI \<18.5 Kg/m2~* Hemoglobin A1c (HbA1c)\>10.0% or \<7.0%~* Active liver disease and/or significant abnormal liver function~* Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma~* Congestive heart failure defined as New York Heart Association (NYHA) class III or IV and /or left ventricular ejection fraction ≤40%~* Significant cardiovascular history with the past 6 months~* Severe retinopathy, persistent uncontrolled hypertension (SBP≥180mmHg, or DBP≥105mmHg)~* Severe chronic gastrointestinal disease~* History of alcohol abuse or illegal drug abuse within the past 12 months~* Diagnosed anemia~* Creatine kinase ≥3 X ULN~* Serum creatinine ≥1.5 mg/dL(133μmol/L) \[males\], ≥1.4 mg/dL(124 μmol/L)\[females\]~* Alanine amino transferase (ALT) and/or aspartate amino transferase (AST)\> 1.5 X ULN and/or total bilirubin \> 2 X ULN~* Hemoglobin \<12g/dL \[males\], \<11g/dL \[females\]~* Allergies and Adverse Drug Reactions~* Prohibited Treatments and/or Therapies~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness~* Subjects decline to participate

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): Normal Weight by Body Weight Index
- A2 (Type: EXPERIMENTAL): Overweight by Body Weight Index
- A3 (Type: EXPERIMENTAL): Obese by Body Weight Index

Based on this trial design, predict the completion outcome and termination type (if applicable).